| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 138, Issue 1 157-163, Copyright © 1987 by American Association of Immunologists
ARTICLES |
JD Mountz, HR Smith, RL Wilder, JP Reeves and AD Steinberg
MRL-lpr/lpr mice spontaneously develop massive T cell lymphadenopathy, autoantibodies, and immune-mediated pathology. These mice are thought to be models of various human autoimmune diseases, including systemic lupus, Sjogren's syndrome, and rheumatoid arthritis. We have used cyclosporin A (CS-A) treatment as a tool by which the mechanisms of immune-mediated pathology might be dissected. CS-A was used because of its known preferential inhibition of T cell function and the marked expansion in MRL-lpr/lpr mice of an unusual L3T4-, Lyt-2-, 6B2+ T cell population. CS-A prevented lymphadenopathy and expansion of L3T4-, Lyt- 2-, 6B2+ T cells in the peripheral lymph nodes, and also in the thymus. The increased expression of the c-myb and T cell receptor beta-chain genes associated with these unusual cells was also corrected. The finding of increased numbers of L3T4-, Lyt-2-, 6B2+ thymocytes in untreated mice suggests abnormal intrathymic differentiation in lpr/lpr mice, a defect that was corrected by CS-A. Treated mice had a marked decrease in arthritis and glomerulonephritis and significantly prolonged survival. These beneficial effects of CS-A occurred despite a lack of reduction in antibodies reactive with DNA, circulating immune complexes, rheumatoid factor titers, or immunoglobulin concentrations. These results demonstrate that the B cell hyperactivity of MRL-lpr/lpr mice can proceed without the T cell proliferative disease.
This article has been cited by other articles:
|
|
 |
|
  L. Lin and S. L. Peng Coordination of NF-{kappa}B and NFAT Antagonism by the Forkhead Transcription Factor Foxd1. J. Immunol., April 15, 2006; 176(8): 4793 - 4803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Bloom, T. O'Connor, B. Cizman, R. Kalluri, A. Naji, and M. P. Madaio Intrathymic kidney cells delay the onset of lupus nephritis in MRL-lpr/lpr mice Int. Immunol., August 1, 2002; 14(8): 867 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Liang, M. J. Kashgarian, A. H. Sharpe, and M. J. Mamula Autoantibody Responses and Pathology Regulated by B7-1 and B7-2 Costimulation in MRL/lpr Lupus J. Immunol., September 15, 2000; 165(6): 3436 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Korner, E. Cretney, P. Wilhelm, J. M. Kelly, M. Rollinghoff, J. D. Sedgwick, and M. J. Smyth Tumor Necrosis Factor Sustains the Generalized Lymphoproliferative Disorder (gld) Phenotype J. Exp. Med., January 3, 2000; 191(1): 89 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tada, K. Nagasawa, A. Ho, F. Morito, S. Koarada, O. Ushiyama, N. Suzuki, A. Ohta, and T. W. Mak Role of the Costimulatory Molecule CD28 in the Development of Lupus in MRL/lpr Mice J. Immunol., September 15, 1999; 163(6): 3153 - 3159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Straus, M. Sneller, M. J. Lenardo, J. M. Puck, and W. Strober An Inherited Disorder of Lymphocyte Apoptosis: The Autoimmune Lymphoproliferative Syndrome Ann Intern Med, April 6, 1999; 130(7): 591 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Sneller, J. Wang, J. K. Dale, W. Strober, L. A. Middelton, Y. Choi, T. A. Fleisher, M. S. Lim, E. S. Jaffe, J. M. Puck, et al. Clinical, Immunologic, and Genetic Features of an Autoimmune Lymphoproliferative Syndrome Associated With Abnormal Lymphocyte Apoptosis Blood, February 15, 1997; 89(4): 1341 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lebrun, W. Burny, J.-P. Cosyns, and J.-M. R. Saint-Remy Injections of Complexes made of dsDNA and Specific Polyclonal Antibodies Extend MRL LPR Mouse Survival: a Pilot Study Lupus, February 1, 1994; 3(1): 47 - 53. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
